维持性血透患者血浆转化生长因子β_1水平及其临床意义

CLINICAL ASSOCIATION OF INCREASED PLASMA TGF β1 LEVEL IN MAINTENANCE HEMODIALYSIS PATIENTS

目的 :检测维持性血液透析 (MHD)患者血浆转化生长因子 β1(TGF β1)水平并探讨其可能的临床意义。 方法 :应用竞争性酶联免疫法 (ELISA)测定 2 7例MHD患者和 2 0例健康对照者TGF β1水平。 结果 :与正常对照组相比 ,MHD患者血浆TGF β1水平明显增加 (82 9± 9 80vs 5 0 2± 5 70 ,P <0 0 1)。但血浆TGF β1水平与血Hct无明显相关关系 (r=0 15 2 ,P >0 0 5 )。另外 ,患者血浆TGF β1水平与接受rHuEPO治疗的剂量之间亦无明显相关性。将MHD患者按血浆iPTH水平分成小于和大于 2 0 0ng/L两组 ,发现两组间血浆TGF β1水平有明显统计学差异 (72 1± 4 6 0vs 93 7± 6 5 0ng/L ,P <0 0 5 ) ,但所有MHD患者血浆TGF β1与iPTH水平之间无明显相关性 (r =0 2 5 7,P >0 0 5 )。 结论 :MHD患者TGF β1水平增加可能与尿毒症的某些并发症有关 。

Plasma level of transforming growth factor(TGF)β 1 has been reported increased in maintenance hemodialysis(MHD)patients,while its clinical significance remained not extensively explored.In this study,we determined the plasma TGF β 1 in 27 MHD patients and explored its association with uremic complications as uremic anemia and secondary hyperparathyroidism. METHODOLOGY Plasma level of TGF β 1 was determined with a solid phase ELISA in 27 MHD patients and 20 healthy control subjects.Clinical data of uremic complications were analyzed with respect to the plasma TGF β 1 levels. RESULTS Compared to the controls,the MHD patients had significantly higher mean TGF β 1 level(82 9±9 80 vs 50 2±5 70 μg/L, P <0 01).No correlation was found between the plasma TGF β 1 level and the hematocrit in these patients( r =0 152, P >0 05),and no correlation between the plasma TGF β 1 level and the dosage of erythropoietin(EPO)treatment.Among these MHD patients,the average level of plasma TGF β 1 was found significantly higher in patients whose serum iPTH levels below 200 ng/L than those above(72 1±4 60 vs 93 7±6 50 ng/L, P <0 05),while no correlation was found between the serum iPTH level and the plasma TGF β 1 level( r =0 257, P >0 05). CONCLUSION ]